-
Product Insights
Likelihood of Approval Analysis for Juvenile Arthritis
Overview How likely is it that the drugs in Juvenile Arthritis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Juvenile Arthritis Overview Juvenile arthritis (JA), also known as pediatric rheumatic disease,...
-
Product Insights
Likelihood of Approval Analysis for Type 1 Diabetes (Juvenile Diabetes)
Overview How likely is it that the drugs in Type 1 Diabetes (Juvenile Diabetes) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Type 1 Diabetes (Juvenile Diabetes) Overview Type 1 diabetes,...
-
Product Insights
Likelihood of Approval Analysis for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
Overview How likely is it that the drugs in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Overview Systemic-onset...
-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Juvenile Macular Degeneration Clinical Trial Report Overview A total of 59 Juvenile Macular Degeneration clinical trials were conducted as of April 2024. The Juvenile Macular Degeneration clinical trial report provides a comprehensive understanding of the Juvenile Macular Degeneration clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Luminol Monosodium in Juvenile Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luminol Monosodium in Juvenile Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luminol Monosodium in Juvenile Arthritis Drug Details: MP-1032 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TLX-66 in Juvenile Myelomonocytic Leukemia (JMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TLX-66 in Juvenile Myelomonocytic Leukemia (JMML) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TLX-66 in Juvenile Myelomonocytic Leukemia (JMML) Drug Details: TLX-66...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Baqsimi in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Baqsimi in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Baqsimi in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aldesleukin in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aldesleukin in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aldesleukin in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volagidemab in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Volagidemab in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Volagidemab in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sarilumab in Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sarilumab in Polyarticular Juvenile Idiopathic Arthritis (PJIA) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sarilumab in Polyarticular Juvenile Idiopathic Arthritis (PJIA) Drug Details:...